These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 39232591)
1. Evaluation of the effect of botulinum toxin A on the physical and mental health of patients with hemifacial spasm. Wei JS; Hu X; Xia L; Shang J; Han Q; Zhang DY Neurologia (Engl Ed); 2024 Sep; 39(7):540-548. PubMed ID: 39232591 [TBL] [Abstract][Full Text] [Related]
2. Botulinum toxin A improves psychological distress in patients with hemifacial spasm. Wang C; Zhu X; Xia L; Xie P; Tian X; Shang J; Han Q Acta Neurol Belg; 2022 Feb; 122(1):43-49. PubMed ID: 33515182 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of stigmatization in hemifacial spasm and quality of life before and after botulinum toxin treatment. Yuksel B; Genc F; Yaman A; Goksu EO; Ak PD; Gomceli YB Acta Neurol Belg; 2019 Mar; 119(1):55-60. PubMed ID: 30178181 [TBL] [Abstract][Full Text] [Related]
4. Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy. Rudzińska M; Wójcik M; Szczudlik A J Neural Transm (Vienna); 2010 Jun; 117(6):765-72. PubMed ID: 20467763 [TBL] [Abstract][Full Text] [Related]
5. Hemifacial spasm through the last three decades: From etiology to efficacy and safety of long-term botulinum toxin treatment. Herrero-Infante Y; Rodríguez-Sanz A; Máñez-Miró J; Vivancos-Matellano F Clin Neurol Neurosurg; 2021 Apr; 203():106555. PubMed ID: 33662742 [TBL] [Abstract][Full Text] [Related]
6. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study. Kongsengdao S; Kritalukkul S J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887 [TBL] [Abstract][Full Text] [Related]
7. The influence of botulinum toxin on auditory disturbances in hemifacial spasm. Rudzińska M; Wójcik M; Zajdel K; Hydzik-Sobocińska K; Malec M; Hartel M; Składzień J; Szczudlik A Neurol Neurochir Pol; 2012; 46(1):29-36. PubMed ID: 22426760 [TBL] [Abstract][Full Text] [Related]
8. Factors affecting the quality of life in hemifacial spasm patients. Rudzińska M; Wójcik M; Malec M; Grabska N; Szubiga M; Hartel M; Szczudlik A Neurol Neurochir Pol; 2012; 46(2):121-9. PubMed ID: 22581593 [TBL] [Abstract][Full Text] [Related]
9. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm. Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439 [TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Defazio G; Abbruzzese G; Girlanda P; Vacca L; Currà A; De Salvia R; Marchese R; Raineri R; Roselli F; Livrea P; Berardelli A Arch Neurol; 2002 Mar; 59(3):418-20. PubMed ID: 11890846 [TBL] [Abstract][Full Text] [Related]
11. Is it always necessary to apply botulinum toxin into the lower facial muscles in hemifacial spasm?: a randomized, single-blind, crossover trial. Colakoglu BD; Cakmur R; Uzunel F Eur Neurol; 2011; 65(5):286-90. PubMed ID: 21502764 [TBL] [Abstract][Full Text] [Related]
12. Treatment with botulinum toxin improves the hyperexcitability of the facial motoneuron in patients with hemifacial spasm. Ishikawa M; Takashima K; Kamochi H; Kusaka G; Shinoda S; Watanabe E Neurol Res; 2010 Jul; 32(6):656-60. PubMed ID: 19660185 [TBL] [Abstract][Full Text] [Related]
13. Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm. Pandey S; Jain S Neurol India; 2018; 66(4):1036-1042. PubMed ID: 30038089 [TBL] [Abstract][Full Text] [Related]
14. A Study on Clinical Profile of Hemifacial Spasm in India and the Therapeutic Response to Botulinum Toxin Type A Injection as well as Pre and Postinjection Quality of Life. Misra AK; Mukherjee J; Kumar S; Guha G; Mohanty B; Ngullie PS; Manna A; Nanda T; Das AK; Tiwari K J Assoc Physicians India; 2022 Dec; 70(12):11-12. PubMed ID: 37355970 [TBL] [Abstract][Full Text] [Related]
16. Clinical features and treatment status of hemifacial spasm in China. Wang L; Hu X; Dong H; Wang W; Huang Y; Jin L; Luo Y; Zhang W; Lian Y; Liang Z; Shang H; Feng Y; Wu Y; Chen J; Luo W; Wan X Chin Med J (Engl); 2014; 127(5):845-9. PubMed ID: 24571874 [TBL] [Abstract][Full Text] [Related]
17. Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated. Batisti JP; Kleinfelder AD; Galli NB; Moro A; Munhoz RP; Teive HA Arq Neuropsiquiatr; 2017 Feb; 75(2):87-91. PubMed ID: 28226076 [TBL] [Abstract][Full Text] [Related]
18. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm. Bayraktar Bilen N; Bilen Ş; Topçu Yılmaz P; Evren Kemer Ö Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169 [TBL] [Abstract][Full Text] [Related]
19. Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies. Tambasco N; Filidei M; Nigro P; Parnetti L; Simoni S Toxins (Basel); 2021 Dec; 13(12):. PubMed ID: 34941718 [TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin improves quality of life in hemifacial spasm: validation of a questionnaire (HFS-30). Tan EK; Fook-Chong S; Lum SY; Lim E J Neurol Sci; 2004 Apr; 219(1-2):151-5. PubMed ID: 15050451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]